Navigation Links
Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior
Date:2/4/2008

/CAUTION -- ADVANCE FOR RELEASE AT 5 P.M. EST MONDAY, FEB. 4/

/ADVANCE/ ROCKVILLE, Md., Feb. 4 /PRNewswire-USNewswire/ -- Patients who undergo complete prostate removal are less likely to experience urinary incontinence or other complications if the operation is done by an experienced surgeon in a hospital that does many of the procedures, according to a report funded by the Agency for Healthcare Research and Quality, part of the U.S. Department of Health and Human Services.

However, the new report concludes that scientific evidence has not established surgery or any other single treatment as superior for all men. The analysis compared the effectiveness and risks of eight prostate cancer treatments, ranging from prostate removal to radioactive implants to no treatment. An article based on the report is posted today in the online version of the Annals of Internal Medicine.

"This report is a reminder that patient outcomes may vary according to treatment settings," said AHRQ Director Carolyn M. Clancy, M.D. "But this analysis also underscores a broader message: when it comes to prostate cancer, we have much to learn about which treatments work best, and patients should be informed about the benefits and harms of treatment options."

The prostate gland, which is about the size of a walnut, is located just below the bladder. It makes and stores the liquid that carries sperm. In 2007, about 218,000 men were diagnosed with prostate cancer, and about 27,050 men died from the disease. The primary goals of treatment are to determine whether an intervention is needed to prevent death and disability and to minimize complications. Treatment choices often take into account a patient's age, race, ethnicity, health status, family history, patient preferences and how quickly the cancer is likely to spread.

The lifetime risk of being diagnosed with prostate cancer has nearly doubled to 20 percent since the late 1980s, due mostly to expanded use of the Prostate Specific Antigen (PSA) blood test. But the risk of dying of prostate cancer remains about 3 percent. Therefore, considerable overdetection and overtreatment may exist. The U.S. Preventive Services Task Force, a panel of outside experts convened by AHRQ that makes independent evidence-based recommendations, maintains there is insufficient evidence to recommend for or against PSA testing for routine prostate cancer screening. PSA tests can detect early-stage cancer when it is potentially most treatable but also lead to frequent false-positive results and identification of prostate cancers unlikely to cause harm.

AHRQ's new report, based on a review of 592 published articles, compared eight prostate cancer strategies: complete surgical removal of prostate and related tissue; minimally invasive surgery to remove the prostate; external radiation; radioactive implants; destruction of cancer cells through rapid freezing and thawing; removal of testicles or hormone therapy; high-intensity ultrasound; and no immediate treatment, also known as "watchful waiting."

The report, compiled by AHRQ's Minnesota Evidence-based Practice Center, is intended to provide unbiased, evidence-based information so that patients, clinicians and others can make the best treatment decisions possible. Among its conclusions:

-- Not enough scientific evidence exists to identify any prostate cancer treatment as most effective for all men, especially those whose cancers were found by PSA testing. However, more than 90 percent of patients reported they would make the same treatment decision again, regardless of the treatment they received.

-- All treatment options cause health problems, primarily urinary incontinence, bowel problems and erectile dysfunction. The chances of bowel problems or sexual dysfunction are similar for surgery and external radiation. Leaking of urine is at least six times more likely among surgery patients than those treated by external radiation.

-- One study showed that men who choose surgery over watchful waiting are less likely to die or have their cancer spread. The benefit appears to be limited to men under 65. However, because few patients in this study had cancer detected through PSA tests, it is unknown if this finding would apply to those whose cancers were detected through PSA screening. Another smaller study showed no difference in survival between surgery and watchful waiting.

-- Among patients who choose surgery, urinary complications and incontinence are less likely if their surgeons performed more than 40 prostate removals per year.

-- Surgery-related deaths, urinary complications and readmissions were lower and hospital stays were shorter in hospitals that performed more prostate removals.

-- A lack of research makes it impossible to compare several treatments: rapid freezing and thawing (cryotherapy); minimally invasive surgery (laparoscopic or robotic assisted radical prostatectomy); testicle removal or hormone therapy (androgen deprivation therapy); and high-intensity ultrasound or radiation therapy.

-- Adding hormone therapy prior to prostate removal does not improve survival or decrease recurrence rates, but it does increase the chance of adverse events.

-- Combining radiation with hormone therapy may decrease mortality. But compared with radiation treatment alone, the combination increases the chances of impotence and abnormal breast development.

The report released today, Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer, is the newest analysis from AHRQ's Effective Health Care program. This AHRQ program represents an important federal effort to compare treatments for significant health conditions and make the findings public. The Effective Health Care program also translates reports into plain-language guides for clinicians, patients and policymakers. Information on the program, including full reports and summary guides, can be found at http://www.effectivehealthcare.ahrq.gov.


'/>"/>
SOURCE Agency for Healthcare Research & Quality
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
2. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
3. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
4. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
5. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
6. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
7. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... PUNE, India , February 23, 2017 ... "Diagnostic Imaging Market by Product (X-ray Imaging Digital, Analog), ... PET)), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, ... MarketsandMarkets, the report studies the global market over the ... expected to reach ~USD 36.43 Billion by 2021, at ...
(Date:2/23/2017)... , Feb. 23, 2017  As National ... In addition, the Company is helping people live ... its customized prescription savings programs in all 50 ... Prescription Assistance Program  and  California Prescription Assistance Program ... from Columbia University for nutritious eating ...
(Date:2/23/2017)... , Feb. 23, 2017 LG Innotek today announced ... for sterilization applications. As its sterilization performance is 1.5 times higher ... short wavelength ultraviolet rays in the range of 200 -- 280nm, allowing ... of bacteria by destroying their DNA. LG Innotek,s product emits UV ... ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... On ... issued a letter to withdraw previous guidance issued by the Obama ... The guidance issued in May 2016 by the Obama Administration came in response ...
(Date:2/23/2017)... ... 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. ... Not to Hot,” which will begin airing on February 24, 2017. The show chronicles ... the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, a comprehensive ... was named a 2017 Top Patient Rated Henderson Dentist by Find Local ... recognizes local physicians and dentists who have earned high ratings and superior patient reviews ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... HealthPostures, the ... sending an expert sit stand solutions representative to the Minneapolis Home and Garden Show ... for the event that is garnering national attention is the Minneapolis Convention Center. ...
Breaking Medicine News(10 mins):